



Programs & Services Committee Agenda

City of Newton In City Council

Wednesday, April 22, 2020

The Programs & Services Committee will hold this meeting as a virtual meeting on Wednesday, April 22, 2020 at 7:00 pm. To view this meeting use this link at the above date and time: <https://zoom.us/j/452656555>. To listen to this meeting via phone call 1-646-558-8656 and enter the meeting ID 452 656 555.

Items Scheduled for Discussion:

- #48-20** **Request for a discussion regarding Senior Services outreach**
COUNCILORS ALBRIGHT AND GREENBERG requesting a discussion with the Department of Senior Services regarding outreach and services to the growing number of Newton residents who are 85 and older yet living alone. Discussion should focus on the City's efforts to provide a program; whether through current programs or proposed alternatives.
Programs and Services Held 8-0 on 03/18/2020
- #239-20** **Referred to Programs & Services and Finance Committees**
Allocate \$500,000 to control the spread of COVID-19
HER HONOR THE MAYOR requesting authorization to allocate five hundred thousand dollars (\$500,000) to a non-lapsing account dedicated to the City's efforts to control the spread of COVID-19; additionally re-classify the previously approved \$250,000 to the same account and allow the administration to disburse these funds to support compensation, supplies, or other accounts as necessary.

The location of this meeting is accessible and reasonable accommodations will be provided to persons with disabilities who require assistance. If you need a reasonable accommodation, please contact the City of Newton's ADA Coordinator, Jini Fairley, at least two business days in advance of the meeting: jfairley@newtonma.gov or (617) 796-1253. The city's TTY/TDD direct line is: 617-796-1089. For the Telecommunications Relay Service (TRS), please dial 711.

- #179-20 Reappointment of Ted Kuklinski to the Off-Leash Dog Task Force**
COUNCILOR ALBRIGHT requesting the reappointment of TED KUKLINSKI, 24 Henshaw Terrace, West Newton, as a member of the OFF-LEASH DOG TASK FORCE for a term to expire on December 31, 2021. (60 days: 05/15/20)
- #180-20 Reappointment of Mary Lee Belleville to the Off-Leash Dog Task Force**
COUNCILOR ALBRIGHT requesting the reappointment of MARY LEE BELLEVILLE, 136 Warren Street #1, Newton Centre, as a member of the OFF-LEASH DOG TASK FORCE for a term to expire on December 31, 2021. (60 days: 05/15/20)
- #181-20 Reappointment of Amy Koel to the Off-Leash Dog Task Force**
COUNCILOR ALBRIGHT requesting the reappointment of AMY KOEL, 70 Waverley Avenue, Newton, as a member of the OFF-LEASH DOG TASK FORCE for a term to expire on December 31, 2021. (60 days: 05/15/20)
- #216-20 Reappointment of Lee McIntyre as a member of the Off-Leash Dog Task Force**
PRESIDENT ALBRIGHT requesting the reappointment of Lee McIntyre, 607 Commonwealth Avenue, Newton, as a member of the OFF-LEASH DOG TASK FORCE for a term to expire on December 31, 2021. (60 days: 06/05/2020)

- #182-20 Reappointment of James Harper to the Farm Commission**
HER HONOR THE MAYOR reappointing JAMES HARPER, 59 Westminster Road, Newton Center, as a member of the FARM COMMISSION for a term to expire on March 31, 2023. (60 days: 05/15/20)
- #183-20 Reappointment of Vaunita Schnell to the Farm Commission**
HER HONOR THE MAYOR reappointing VAUNITA SCHNELL. 68 Stearns Street, Newton Center, as a member of the FARM COMMISSION for a term to expire on March 31, 2023. (60 days: 05/15/20)
- #214-20 Reappointment of William Dietrich as a member of the Biosafety Committee**
COUNCILOR ALBRIGHT requesting the reappointment of William Dietrich, 28 Osbourne Path, Newton, to the BIOSAFETY COMMITTEE for a term to expire on May 4, 2023. (60 days: 06/05/2020)
- #215-20 Reappointment of Gary du Moulin as a member of the Biosafety Committee**
COUNCILOR ALBRIGHT requesting the reappointment of Gary du Moulin, 24 Myerson Lane, Newton Centre, to the BIOSAFETY COMMITTEE for a term to expire on May 4, 2023. (60 days: 06/05/2020)

Respectfully Submitted,

Josh Krintzman, Chair



RUTHANNE FULLER
MAYOR

City of Newton, Massachusetts

RECEIVED
Office of the Mayor

2020 APR 13 PM 12:16

CITY CLERK
NEWTON, MA. 02459

239-20

Telephone
(617) 796-1100

Telefax
(617) 796-1113

TDD
(617) 796-1089

E-mail
rfuller@newtonma.gov

April 13, 2020

Honorable City Council
Newton City Hall
1000 Commonwealth Avenue
Newton Centre, MA 02459

In the midst of the COVID-19 pandemic, I am focused on taking care of our vulnerable citizens, paying our employees when they work a significant number of hours to help people, and providing the supplies necessary to protect our first responders and essential workers.

Therefore, I am requesting that the City of Newton allocate another \$500,000 to a non-lapsing account dedicated to our efforts to control the spread of COVID-19, as well as, re-classify the previously approved \$250,000 to the same account, and allow the administration to disburse these funds to support compensation, supplies, or other accounts as necessary.

These \$750,000 in funds, along with the \$200,000 from the Massachusetts Department of Public Health COVID-19 Emergency Grant, put us in a strong position to meet the many needs we are facing.

We will carefully track utilization of these funds and will be sure to charge as many dollars as are appropriate to any grants we receive and seek the maximum reimbursements possible. We will keep your Honorable Council apprised.

Thank you for your consideration of this matter.

Sincerely,

Ruthanne Fuller
Mayor



Ruthanne Fuller
Mayor

City of Newton, Massachusetts
Office of the Mayor

Telephone
(617) 796-1100
Fax
(617) 796-1113
TDD/TTY
(617) 796-1089
Email
rfuller@newtonma.gov

February 21, 2020

Honorable City Council
Newton City Hall
1000 Commonwealth Avenue
Newton, MA 02459

To the Honorable City Councilors:

I am pleased to reappoint James Harper of 59 Westminster Road, Newton Center as a member of the Farm Commission. His term of office shall expire on March 31, 2023 and his appointment is subject to your confirmation.

Thank you for your attention to this matter.

Warmly,

Ruthanne Fuller
Mayor

CITY CLERK
NEWTON, MA. 02459

2020 MAR -4 AM 9:52

RECEIVED

Application Form

Profile

James (Jim) _____ J _____ Harper _____
 First Name Middle Initial Last Name

 Email Address

59 Westminster Rd. _____
 Home Address

59 WESTMINSTER RD _____
 Suite or Apt

NEWTON CENTRE _____
 City

MA _____ 02459 _____
 State Postal Code

What Ward do you live in?

Ward 7

 Primary Phone

 Alternate Phone

N/A -- Retired _____
 Employer

CPA _____
 Job Title

Which Boards would you like to apply for?

Farm Commission: Submitted

Interests & Experiences

Please tell us about yourself and why you want to serve.

Why are you interested in serving on a board or commission?

I wish to continue to serve on the Farm Commission, as I have been interested in the Angino Farm since it was acquired by the City.

Jim Harper Resume Jun 18 1 .docx

Upload a Resume

JAMES J. HARPER, CPA
59 Westminster Road, Newton, MA 02459

PROFILE

Retired tax professional with additional expertise in financial reporting and control. Tax experience encompassed a range of industries and work with the IRS at the agent, Appeals and National Office levels. Reputation for high integrity, insight and creativity in managing the tax and accounting functions.

PROFESSIONAL EXPERIENCE

RETIRED

2014 to Present

IRON MOUNTAIN INCORPORATED, Boston, MA

2005 to 2014

\$3 billion storage and information management services company with more than 1,000 facilities in 36 countries.

Tax Director

Responsible for domestic corporate tax planning, accounting, return compliance and tax audits and appeals.

- Favorably concluded two IRS audits resulting in release of substantial reserves.
- Oversaw tax integration of several acquisitions and a major disposition.
- Assisted with preparation for Iron Mountain to become a Real Estate Investment Trust

SELF-EMPLOYED CORPORATE TAX CONSULTANT

2000 to 2005

Following KeySpan Energy's acquisition of Eastern Enterprises, assisted KeySpan with tax and accounting transition issues, including work on golden parachutes, tax planning for dispositions, pre-merger tax compliance, tax basis studies and merger accounting. Assisted Iron Mountain with corporate tax planning, accounting and return compliance.

EASTERN ENTERPRISES, Weston, MA

1975 to 2000

\$1 billion diversified holding company with both regulated and non-regulated operations, the latter of which over time included inland marine transportation, coal mining, oil and gas, distribution of water pipe and the manufacture and service of ultrapure water equipment. Acquired by Keyspan Energy in November 2000, creating the largest gas utility in the Northeast.

Vice President and Controller (1987 to 2000)

Responsible for corporate tax planning, accounting, return compliance, and IRS audits and appeals. Chief Accounting Officer responsible for 10-K and 10-Q filings. Also responsible for MIS operations supporting headquarters staff of 45.

- Reached favorable RAR settlement, including research credit for internal use software and current deductions for cyclical maintenance and reengineering, despite widely publicized IRS opposition to these items.
- Structured the operations of Ionpure, which manufactured and serviced ultrapure water equipment from 1989 until its sale in 1993. This \$50 million division operated internationally
- through seven subsidiaries in Europe and through agents in other countries.

JAMES J. HARPER, CPA

Page 2

- **EASTERN ENTERPRISES** (continued)
- Oversaw tax compliance in more than 30 states.
- Coordinated successful industry response to IRS proposal to capitalize gas utility deregulation costs.
- Created tax-free structures at the corporate level for three recent acquisitions, including Essex County Gas in 1998, Colonial Gas in 1999, and Energy North in 2000. Conducted tax due diligence for these companies and two other potential targets.
- Managed integration into KeySpan, identifying synergy costs, completing acquisition accounting and ensuring tax compliance.
- Structured sales of subsidiaries in 1993 and 1995 to maximize tax benefits.
- Converted legacy mainframe ledger and payables systems to PC-based systems in early 1990s.
- Managed implementation of optical storage system for accounting records.

Assistant Vice President, Taxes (1981 to 1987)

Responsible for tax planning and accounting, return compliance and audits.

- Lowered tax rate through elections to capitalize coal operations repairs, which in turn generated additional investment credit and percentage depletion.
- Structured sale of coal operations to create large artificial tax loss.

Tax Manager (1975 to 1981)

Responsible for tax planning and accounting, return compliance and audits.

- Created in-house tax return system used by company for ten years.
- Created automated system for tax compliance for oil and gas operations.

ARTHUR ANDERSEN & CO., Boston, MA

1972 to 1975

Tax Senior

Responsible for domestic and international research, planning and compliance for a client base consisting of utility, manufacturing and individual clients.

US PEACE CORPS, Philippines

1968 to 1970

Worked in the development and planning office of a small city in Southern Luzon.

EDUCATION

MS, Taxation, Bentley College, Waltham, MA, 1978

MBA, Harvard Business School, Cambridge, MA, 1972

BA, History, Economics and Government, magna cum laude, phi beta kappa, Wesleyan University, Middletown, CT, 1967

PROFESSIONAL AFFILIATIONS

Past Chair of Federal Tax Committee, New England Chapter of Tax Executives Institute

Past Chair of Tax Committee, American Gas Association



Ruthanne Fuller
Mayor

City of Newton, Massachusetts
Office of the Mayor

#183-20

Telephone
(617) 796-1100

Fax
(617) 796-1113

TDD/TTY
(617) 796-1089

Email
rfuller@newtonma.gov

February 21, 2020

Honorable City Council
Newton City Hall
1000 Commonwealth Avenue
Newton, MA 02459

To the Honorable City Councilors:

I am pleased to reappoint Vaunita Schnell of 68 Stearns Street, Newton Center as a member of the Farm Commission. Her term of office shall expire on March 31, 2023 and her appointment is subject to your confirmation.

Thank you for your attention to this matter.

Warmly,

Ruthanne Fuller
Mayor

CITY CLERK
NEWTON, MA. 02459

2020 MAR -4 AM 9:52

RECEIVED

Application Form

Profile

Vaunita _____ Schnell _____
First Name Middle Initial Last Name

[Redacted] _____
Email Address

68 Stearns St. _____ Suite or Apt _____
Home Address

Newton Centre _____ MA _____ 02459 _____
City State Postal Code

What Ward do you live in?

Ward 6

[Redacted] _____ Home: _____
Primary Phone Alternate Phone

Retired _____ Educator _____
Employer Job Title

Which Boards would you like to apply for?

Farm Commission: Submitted

Interests & Experiences

Please tell us about yourself and why you want to serve.

Why are you interested in serving on a board or commission?

Current member of the board. Former farmer with agricultural experience. Founding member of the farm. As an educator I am very interested in teaching young people about the farm.

Upload a Resume

5/21/18 ①

Wae

Vivian Schell
 68 Stearns St.
 Newton Centre, Mass. 02459

Education

Fort Hays Kansas State College B.A. English
 Hays, Kansas Graduated 1957

Purdue University MA Guidance/Counseling
 West Lafayette, Ind. Graduated 1963

Experience

Argentine High School
 Kansas City, KS

1957-1960
 English/Journalism Teacher

Emery Bird Thayer
 Kansas City, MO

Copywriter
 1959-1961

University of Chicago Laboratory School Counselor/acting
 Chicago, Ill. Director
 1965-1969

Day Middle School
 Newton, Mass.

Counselor, Director of
 1973-1983 Guidance

Newton North High School
 Newton, Mass.

Counselor
 1983-1987

②

Newton South High School Counselor, 1987-1994
 Newton, Mass. Director of Guidance
 1995-2003

Northeastern University Adjunct professor
 Boston, Mass. 1996-2002

Publications

Approximately 20 publications in the field of guidance & counseling - presented at state and national conventions and in local and national journals.

Honors

Several honor societies in both high school and college. Outstanding education award.

Volunteer activities

About 20 various organizations over the years. In Newton, member (past) of the Newton Conservation Commission. Past president and current board member of the Friends of Hembels Gorge. Founder of the Newton Community Farm along with a group headed by the Conservation Commission. In Mass, President (past) of the Child Study Assn.

CITY OF NEWTON

DOCKET REQUEST FORM

DEADLINE NOTICE: Council Rules require items to be docketed with the Clerk of the Council NO LATER THAN 7:45 P.M. ON THE MONDAY PRIOR TO A FULL COUNCIL MEETING.

To: Clerk of the City Council

Date: 03/13/2020

From (Docketer): Councilor Albright

Address: _____

Phone: _____

E-mail: _____

Additional sponsors: _____

1. Please docket the following item (it will be edited for length if necessary):

Requesting the reappointment of William Dietrich, 28 Osbourne Path, Newton, as a member of the Biosafety Committee.

RECEIVED
2020 MAR 13 PM 2:43
CITY CLERK
NEWTON, MA. 02459

2. The purpose and intended outcome of this item is:

- Fact-finding & discussion
- Appropriation, transfer,
- Expenditure, or bond authorization
- Special permit, site plan approval,
- Zone change (public hearing required)

- Ordinance change
- Resolution
- License or renewal
- Appointment confirmation
- Other: _____

3. I recommend that this item be assigned to the following committees:

- | | | |
|---|--|--|
| <input checked="" type="checkbox"/> Programs & Services | <input type="checkbox"/> Finance | <input type="checkbox"/> Real Property |
| <input type="checkbox"/> Zoning & Planning | <input type="checkbox"/> Public Safety | <input type="checkbox"/> Special Committee |
| <input type="checkbox"/> Public Facilities | <input type="checkbox"/> Land Use | <input type="checkbox"/> No Opinion |

4. This item should be taken up in committee:

Immediately (Emergency only, please). Please state nature of emergency:

- As soon as possible, preferably within a month
- In due course, at discretion of Committee Chair
- When certain materials are made available, as noted in 7 & 8 on reverse
- Following public hearing

5. I estimate that consideration of this item will require approximately:

- One half hour or less
- More than one hour
- More than one meeting
- Up to one hour
- An entire meeting
- Extended deliberation by subcommittee

6. The following people should be notified and asked to attend deliberations on this item. (Please check those with whom you have already discussed the issue, especially relevant Department Heads):

City personnel

Citizens (include telephone numbers/email please)

- | | |
|--------------------------------|--------------------------------|
| <input type="checkbox"/> _____ | <input type="checkbox"/> _____ |
| <input type="checkbox"/> _____ | <input type="checkbox"/> _____ |
| <input type="checkbox"/> _____ | <input type="checkbox"/> _____ |
| <input type="checkbox"/> _____ | <input type="checkbox"/> _____ |
| <input type="checkbox"/> _____ | <input type="checkbox"/> _____ |

7. The following background materials and/or drafts should be obtained or prepared by the Clerk's office prior to scheduling this item for discussion:

8. I have or intend to provide additional materials and/or undertake the following research independently prior to scheduling the item for discussion. *

(*Note to docketer: Please provide any additional materials beyond the foregoing to the Clerk's office by 2 p.m. on Friday before the upcoming Committee meeting when the item is scheduled to be discussed so that Councilors have a chance to review all relevant materials before a scheduled discussion.)

Please check the following:

- 9. I would like to discuss this item with the Chairman before any decision is made on how and when to proceed.
- 10. I would like the Clerk's office to contact me to confirm that this item has been docketed. My daytime phone number is:
- 11. I would like the Clerk's office to notify me when the Chairman has scheduled the item for discussion.

Thank you.

Councilor Albright
Signature of person docketing the item

[Please retain a copy for your own records]

Application Form

Profile

William F Dietrich
First Name Middle Initial Last Name

[Redacted] Email Address

28 Osborne Path Home Address Suite or Apt

Newton MA 02459
City State Postal Code

What Ward do you live in?

None Selected

[Redacted] Home:
Primary Phone Alternate Phone

Novartis Executive Director
Employer Job Title

Which Boards would you like to apply for?

Biosafety Committee: Submitted

Interests & Experiences

Please tell us about yourself and why you want to serve.

Why are you interested in serving on a board or commission?

I am a long time Newton resident, and I have interest and experience in biology research and the safety issues that occur. I have served already on this committee for the last several years, and I want to renew my membership.

Dietrich_cv-bio.pdf
Upload a Resume

William Frank Dietrich
28 Osborne Path
Newton, MA 02459



Biographical Summary:

Dr. Dietrich is a driven Ph.D biologist with 20 years experience in academia and more than 10 years of leadership experience in the pharmaceutical industry. He has delivered creative and innovative results while working on large collaborative scientific problems such as the Genome Project, genetic determinants of host susceptibility to infectious disease, and drug discovery – these results have taken the form of over 50 primary research publications, pharmacology data to support 6 distinct IND filings, and a patent application. He has successfully worked in hierarchical and matrixed organizations, and is comfortable with initiating and sustaining programs of change in complex organizations.

Title: Executive Director, Discovery and Translational Pharmacology

Office: Novartis Institutes for Biomedical Research



Home Address : 28 Osborne Path
Newton, MA 02459



Date of Birth: [Redacted]



Citizenship: U.S.

- Education:** Massachusetts Institute of Technology, Cambridge, MA (Ph.D in Biology, May 1993)
- Carnegie-Mellon University, Pittsburgh, PA (B.S. in Biological Sciences, June 1987)
- Awards and Honors:** Investigator Award, Howard Hughes Medical Institute (1996-2005)
- Award for Mentoring from the PhD Program in Biological and Biomedical Sciences, Harvard Medical School (September, 2005)
- NIBR Team Award – SMA Team (March, 2014)
- NIBR Diversity and Inclusion Award – Leadership of CIVC Employee Resource Group and Pharmacology Council (April, 2014)
- Volunteer Work:** Member, Newton Biosafety Committee (2014-present)

Research Positions:

Disease Area X (DAX), Novartis Institutes for Biomedical Research (NIBR)
Executive Director, Discovery and Translational Pharmacology, 2016-present
Director, Discovery and Translational Pharmacology (DTP), 2012-2016.

The mission of the DTP Group (currently 32 scientists, 21 in Cambridge, 11 in Basel) is to drive development of medicines for unmet medical needs that are not currently addressed by NIBR disease area strategy. This focused team is aimed at rodent genetic and pharmacology studies to validate and progress drug concepts into the clinic. We do this either by engaging with *de novo* drug discovery programs (D0 through PoC stages) or working to “repurpose” existing NIBR drug assets into use as therapies for additional diseases (D3 through PoC). The vast majority (90%) of our efforts go into programs that are at D3 and beyond. So far, this team has generated pharmacology and other data that supports 3 IND filings.

Developmental and Molecular Pathways, NIBR
Director, Exploratory Pharmacology, 2007-2011.

The major responsibilities of the Exploratory Pharmacology Unit (\approx 25 scientists split into 2 teams in Cambridge and Basel) were directed at using rodent genetics and pharmacology to address two major areas of equal emphasis: 1) supporting target validation and transition of early phase (D0 to D2b) drug discovery programs to our disease area partners for further development, and 2) driving drug discovery programs that are unaligned with disease area partners to the clinic (D0 to PoC). This team has delivered pharmacology data to support 2 IND filings.

Models of Disease Center, NIBR
Director, Mouse Genetics and Toxicology, 2006.

The major responsibilities of the Mouse Genetics and Toxicology Group (20 scientists located in Cambridge) were two-fold: 1) production of mouse models (genetic and otherwise) to support target identification, target validation, estimations of target safety, and efficacy testing of candidate drugs, 2) development of *in vivo* tumor models to support the efficacy testing of Oncology candidate drug compounds. In addition, a small part of my team studied the utility of using genetically diverse inbred mouse strains as an improved method for evaluating human safety of drug candidates.

Department of Genetics, Harvard Medical School

Associate Professor, 2002-2006.

Assistant Professor, 1996-2001.

My academic laboratory (average size \approx 10 scientists) was primarily focused on the study of the genetics of mammalian host response to infectious disease. We identified and studied several genes involved in mouse susceptibility to intracellular pathogens and bacterial toxins. In addition to research support from HHMI, I served as PI on NIH grants AI043321, AI49987, and AI062827.

Center for Genome Research, Whitehead Institute

Research Scientist and Assistant Director, 1992-1995.

As team leader, 1) I directed a group of 7 scientists in the genome center's construction of complete physical and genetic maps for the mouse, 2) I investigated mouse models of cancer using the tools being developed at the genome center by identifying important germline and somatic genetic variants that may be critical in the onset of inherited colon cancer and spontaneous endocrine neoplasias, and 3) I studied the genetic basis of *Legionella pneumophila* susceptibility in inbred strains of mice.

Department of Biology, MIT and Whitehead Institute

Graduate Student, 1987-1992.

1990-1992: I worked on the development of the first complete genetic map of the mouse using highly polymorphic markers that can be analyzed using PCR. This constituted the foundation of the MIT Genome Center's genetic map of the mouse. I applied the map to study the quantitative genetics of mouse models of human disease. These projects included the mapping of genes involved in the inheritance of predisposition to colon cancer (in collaboration with W. Dove at the University of Wisconsin) and genes involved in the onset of type II diabetes (in collaboration with J. Friedman and R. Liebel at Rockefeller University). Advisor: Eric S. Lander.

1987-1989: I worked on projects relating to the development of tools for use in mouse genetics. The primary focus was the identification of species specific repetitive DNA families that could be used to rapidly clone genes in the mouse. Advisor: Hee-Sup Shin.

Department of Biological Sciences, Carnegie-Mellon University

Research Assistant, 1985-1987.

I worked as a synthetic chemist on projects to synthesize and characterize fluorogenic substrate analogs for Beta glucocerebrosidase; these substrate analogs were used to develop rapid assays for patients carrying the Gaucher's Disease allele. Advisor: Alan Waggoner.

Teaching Positions:

Harvard Medical School, Course Director and Lecturer: Genetics 201 (Graduate Course), 1999 - 2003.

Harvard Medical School, Lecturer: Genetics 201 (Graduate Course), 1997 - 1998.

MIT Teaching Assistant: Gene Expression (Graduate Course), Spring, 1991.

MIT Teaching Assistant: Introductory Course in Laboratory Techniques in Biology (Undergraduate Course), Spring, 1989.

Primary Research Publications

Gapp, B., M. Jourdain, P. Bringer, B. Kueng, D. Weber, A. Osmont, S. Zurbruegg, J. Knehr, R. Falchetto, G. Roma, W. Dietrich, R. Valdez, N. Beckmann, F. Nigsch, A. J. Sanyal, and I. Ksiazek. 2019. "FXR agonism, ACC inhibition and back translation of clinically observed endpoints of de novo lipogenesis in a murine NASH model." *Hepatology Comm.*, in press.

E. D. Hernandez, L. Zheng, Y. Kim, B. Fang, B. Liu, R. A. Valdez, W. F. Dietrich, P. V. Rucker, D. Chianelli, J. Schmeits, D. Bao, J. Zoll, C. Dubois, G.C. Federe, L. Chen, S. B. Joseph, L. B. Klickstein, J. Walker, V. Molteni, P. McNamara, S. Meeusen, D. C. Tully, M. K. Badman, J. Xu, and B. Laffitte. 2019. "Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with anti-oxidative gene expression profile in rodents." *Hepatology Comm.*, 3: 1085-1097.

Cheung, A. K., B. Hurley, R. Kerrigan, L. Shu, D. N. Chin, Y. Shen, G. O'Brien, M. Sung, Y. Hou, J. Axford, E. Cody, R. Sun, A. Fazal, R. Tomlinson, M. Jain, L. Deng, K. Hoffmaster, C. Song, M. Van Hoosear, Y. Shin, R. Servais, C. S. Towler, M. Hild, D. Curtis, W. F. Dietrich, L. S. Hamann, K. Briner, K. S. Chen, D. Kobayashi, R. Sivasankaran, and N. A. Dales. 2018. "Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of Spinal Muscular Atrophy (SMA)." *J. Med. Chem.*, 10.1021/acs.jmedchem.8b01291.

Kim, M., L. von Muenchow, T. Le Meur, B. Kueng, B. Gapp, D. Weber, W. Dietrich, J. Kovarik, A. G. Rolink, I. Ksiazek. 2018. "DPP9 enzymatic activity in hematopoietic cells is dispensable for mouse hematopoiesis." *Immunol. Lett.*, 198: 60-65.

Kim, M., M. Minoux, A. Piaia, B. Kueng, B. Gapp, D. Weber, C. Haller, S. Barbieri, K. Namoto, T. Lorenz, J. Wirsching, F. Bassilana, W. Dietrich, F. M. Rijli, and I. Ksiazek. 2017. "Dpp9 enzyme activity controls survival of mouse migratory tongue muscle progenitors and its absence leads to neonatal lethality due to suckling defect." *Devel. Biol.*, 431:297-308.

Kim, M., A. Piaia, N. Shenoy, D. Kagan, B. Gapp, B. Kueng, D. Weber, W. Dietrich, and I. Ksiazek. 2015. "Progression of Alport kidney disease in *Col4a3* knock out mice is independent of sex or macrophage depletion by clodronate treatment." *PLoS One.*, 10(11):e0141231.

Palacino, J., S. E. Swalley, C. Song, A. K. Cheung, L. Shu, X. Zhang, M. VanHoosear, Y. Shin, D. N. Chin, C. Gubser-Keller, M. Beibel, N. A. Renaud, M. Salcius, X. Shi, M. Hild, R. Servais, M. Jain, L. Deng, C. Bullock, M. McLellan, S. Schuierer, L. Murphy, M. J. J. Blommers, C. Blaustein, F. Berenshteyn, A. Lacoste, J. R. Thomas, G. Roma, G. A. Michaud, B. S. Tseng, J. A. Porter, V. E. Myer, J. A. Tallarico, L. G. Hamann, D. Curtis, M. C. Fishman, W. F. Dietrich, N. A. Dales, and R. Sivasankaran. 2015. "SMN2 Splice Modulators Enhance U1-pre-mRNA Association and Rescue SMA Mice." *Nat. Chem. Biol.* 11: 511-517.

Rogers, M. S., V. Boyartchuk, R. M. Rohan, A. E. Birsner, W. F. Dietrich, and R. J. D'Amato. 2012. "The classical pink-eyed dilution mutation affects angiogenic responsiveness." *PLoS One.*, 7: e35237.

Coers, J., I. Bernstein-Hanley, D. Grotzky, I. Parvanova, J. C. Howard, G. A. Taylor, W. F.

Dietrich, and M. N. Starnbach. 2008. "*Chlamydia muridarum* evades growth restriction by the IFN- γ -inducible host resistance factor Irgb10." *J. Immunol.*, 180: 6237-6245.

Lightfield, K. L., J. Persson, S. W. Brubaker, C. E. Witte, J. von Moltke, E. A. Dunipace, T. Henry, Y. H. Sun, D. Cado, W. F. Dietrich, D. M. Monack, R. M. Tsois, and R. E. Vance. 2008. "Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin." *Nature Immunology.*, 9: 1171-1178.

Wang, F., P. N. Paradkar, A. O. Custodio, D. M. McVey Ward, M. D. Fleming, D. Campagna, K. A. Roberts, V. Boyartchuk, W. F. Dietrich, J. Kaplan, and N. C. Andrews. 2007. "Genetic variation in Mon1a affects protein trafficking and modifies macrophage iron loading in mice." *Nature Genetics.*, 39: 1025-1032.

Coers, J., R. E. Vance, M. Fontana, and W. F. Dietrich. 2007. "Restriction of *Legionella pneumophila* growth in macrophages requires the concerted action of cytokine and Naip5/Ipaf signaling pathways." *Cell. Microbiol.*, 9: 2344-2357.

Bernstein-Hanley, I., J. Coers, Z. R. Balsara, G. A. Taylor, M. N. Starnbach, and W. F. Dietrich. 2006. "The p47 GTPases *Igtp* and *Irgb10* map to the *Chlamydia trachomatis* susceptibility locus *Ctrq-3* and mediate cellular resistance in mouse." *Proc. Natl. Acad. Sci. USA.*, 103: 14092-14097.

Ren, T., D. Zamboni, C. R. Roy, W. F. Dietrich, and R. E. Vance. 2006. "Flagellin-deficient *Legionella* mutants evade Caspase-1- and Naip5- mediated macrophage immunity." *PLoS Pathogens.*, 2(3): e18.

Zamboni, D. S., K. S. Kobayashi, T. Kohlsdorf, Y. Ogura, E. M. Long, R. E. Vance, K. Kuida, S. Mariathasan, V. M. Dixit, R. A. Flavell, W. F. Dietrich, and C. R. Roy. 2006. "The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of *Legionella pneumophila* infection." *Nature Immunology.*, 7: 318-325.

Boyden, E. D., and W. F. Dietrich. 2006. "*Nalp1b* controls mouse macrophage susceptibility to anthrax lethal toxin." *Nature Genetics.*, 38: 240-244.

Bernstein-Hanley, I., Z. Balsara, W. Ulmer, J. Coers, M. N. Starnbach, and W. F. Dietrich. 2006. "Genetic analysis of susceptibility to *Chlamydia trachomatis* in mouse." *Genes and Immunity.*, 7: 122-129.

Boyartchuk, V., M. Rojas, B. S. Yan, O. Jobe, N. Hurt, D. M. Dorfman, D. E. Higgins, W. F. Dietrich, and I. Kramnik. 2004. "The host resistance locus *Sst1* controls innate immunity to *Listeria monocytogenes* infection in immunodeficient mice..", *J. Immunol.*, 173: 5112-5120.

Shaw, M. H., V. Boyartchuk, S. Wong, M. Karaghiosoff, J. Ragimbeau, S. Pellegrini, M. Muller, W. F. Dietrich, and G. S. Yap. 2003. "A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity." *Proc. Natl. Acad. Sci. USA.*, 100: 11594-11599.

Wright, E. K., S. A. Goodart, J. D. Gowney, V. Hadinoto, M. G. Endrizzi, E. M. Long, K. Sadigh, A. L. Abney, I. Bernstein-Hanley, and W. F. Dietrich. 2003. "*Naip5* affects host

susceptibility to the intracellular pathogen *Legionella pneumophila*." **Curr. Biol.**, 13: 27-36.

Laprade, L., V. L. Boyartchuk, W. F. Dietrich, and F. Winston. 2002 "Spt3 plays opposite roles in filamentous growth in *S. cerevisiae* and *C. albicans* and is required for *C. albicans* virulence.", **Genetics**, 161: 509-519.

Watters, J. W., K. Dewar, J. Lehoczy, V. Boyartchuk, and W. F. Dietrich. 2001 "Kif1C, a Kinesin-Like Motor Protein, Mediates Mouse Macrophage Resistance to Anthrax Lethal Factor." **Curr. Biol.**, 11: 1503-1511.

Watarai, M., I. Derre, J. Kirby, J. D. Growney, W. F. Dietrich, and R. R. Isberg. 2001 "*Legionella pneumophila* is internalized by a macropinocytotic uptake pathway controlled by the Dot/Icm system and the mouse *Lgn1* locus." **J. Exp. Med.**, 194: 1081-1096.

Boyartchuk, V. L., K. W. Broman, R. E. Mosher, S. E. F. D'Orazio, M. N. Starnbach, and W. F. Dietrich. 2001 "Multigenic control of *Listeria monocytogenes* susceptibility in mice.", **Nature Genetics**, 27: 259 - 260.

Watters, J.W., and W.F. Dietrich. 2001 "Genetic, physical, and transcript map of the *Ltxs1* region of mouse chromosome 11." **Genomics**, 73: 223-231.

Kramnik, I., W. F. Dietrich, P. Demant, and B. R. Bloom. 2000 "Genetic control of resistance to experimental infection with virulent *Mycobacterium tuberculosis*." **Proc. Natl. Acad. Sci. USA**, 97: 8560-8565.

Growney, J. D., and W. F. Dietrich. 2000 "High resolution genetic and physical map of the *Lgn1* interval in C57BL/6J implicates *Naip2* or *Naip5* in *Legionella pneumophila* pathogenesis." **Genome Res.**, 10: 1158-1171.

Endrizzi, M. G., V. Hadinoto, J. D. Growney, W. Miller, and W. F. Dietrich. 2000 "Genomic sequence analysis of the mouse *Naip* gene array." **Genome Res.**, 10: 1095-1102.

Growney, J. D., J. M. Scharf, L. M. Kunkel, and W. F. Dietrich. 2000 "Evolutionary divergence of the mouse and human *Lgn1*/SMA repeat structures." **Genomics**, 64: 62-81.

Nusbaum, C., D. K. Slonim, K. L. Harris, B. W. Birren, R. G. Steen, L. D. Stein, J. Miller, W. F. Dietrich, R. Nahf, V. Wang, O. Merport, A. B. Castle, Z. Husain, G. Farino, D. Gray, M. O. Anderson, R. Devine, L. T. Horton, W. Ye, X. Wu, V. Kouyoumjian, I. S. Zemsteva, Y. Wu, A. J. Collymore, D. F. Courtney, J. Tam, M. Cadman, A. R. Haynes, C. Heuston, T. Marsland, A. Southwell, P. Trickett, M. A. Strivens, M. T. Ross, W. Makalowski, Y. Xu, M. S. Boguski, N. P. Carter, P. Denny, S. D. M. Brown, T. J. Hudson, and E. S. Lander. 1999 "A YAC-based physical map of the mouse genome." **Nature Genetics** 22: 388-393.

von Deimling, F., J. M. Scharf, T. Liehr, M. Rothe, A. -R. Kelter, P. Albers, W. F. Dietrich, L. M. Kunkel, N. Wernert, and B. Wirth. 1999 "Human and Mouse RAD17 genes: identification, localization, genomic structure, and histological expression pattern in normal testis and seminoma." **Hum. Genet.**, 105: 17-27.

Huang, S., J. M. Scharf, J. D. Growney, M. G Endrizzi, and W. F. Dietrich, 1999 "The mouse

Naip gene cluster on chromosome 13 encodes several distinct functional transcripts." **Mamm. Gen.**, 10: 1032-1035.

Endrizzi, M., S. Huang, J. M. Scharf, A. R. Kelter, B. Wirth, L. M. Kunkel, W. Miller, and W. F. Dietrich, 1999 "Comparative sequence analysis of the mouse and human *Lgn1*/SMA interval." **Genomics**, 60: 137-151.

Güler, M. L., J. D. Gorham, W. F. Dietrich, T. L. Murphy, R. G. Steen, C. A. Parvin, D. Fenoglio, A. Grupe, G. Peltz, and K. M. Murphy, 1999 "Tpm-1, a locus controlling IL-12 responsiveness, acts by a cell-autonomous mechanism." **J. Immunol.** 162: 1339-1347.

Scharf, J. M., M. G. Endrizzi, A. Wetter, S. Huang, T. G. Thompson, W. F. Dietrich, B. Wirth, and L. M. Kunkel, 1998 "Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics." **Nature Genetics**, 20: 83-86.

Roberts, J. E., J. W. Watters, J. D. Ballard, and W. F. Dietrich, 1998 "*Ltx1*, a mouse locus which influences the susceptibility of macrophages to cytolysis caused by intoxication with *Bacillus anthracis* lethal factor, maps to chromosome 11." **Molec. Microbio.**, 29: 581-592.

Fleming, M. D., C. C. Trenor, M. A. Su, D. Fornzler, D. Beier, W. F. Dietrich, and N. A. Andrews, 1997 "Microcytic Anaemia Mice have a Mutation in *Nramp2*, a Candidate Iron Transporter." **Nature Genetics**, 16: 383-386.

Fazeli, A., R. G. Steen, S. L. Dickinson, D. Bautista, W. F. Dietrich, R. T. Bronson, R. S. Bresalier, E. S. Lander, J. Costa, and R. A. Weinberg, 1997 "Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas." **Proc. Natl Acad Sci, USA**, 94:10199-10204.

Shi, Y. P., P. Naik, W. F. Dietrich, J. W. Gray, D. Hanahan, and D. Pinkel, 1997 "DNA Copy Number Changes Associated with Characteristic LOH in Islet Cell Carcinomas of Transgenic Mice." **Genes, Chromosomes, and Cancer**, 19:104-111.

Gould, K. A., W. F. Dietrich, N. Borenstein, E. S. Lander, and W. F. Dove, 1996 " *Mom1* is a Semi Dominant Modifier of Intestinal Adenoma Size and Multiplicity in *Min*/+ Mice." **Genetics**, 144: 1769-1776.

Gould, K. A., C. Luongo, A. R. Moser, M. K. McNeley, N. Borenstein, A. Shedlovsky, W. F. Dove, K. Hong, W. F. Dietrich, and E. S. Lander, 1996 "Genetic evaluation of candidate genes for the *Mom1* modifier of intestinal neoplasia in mice." **Genetics**, 144: 1777-1785.

Gorham, J. D., M. L. Güler, R. G. Steen, A. J. Mackey, M. J. Daly, K. Frederick, W. F. Dietrich, and K. M. Murphy, 1996 "Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses" **Proc. Natl. Acad. Sci. USA**, 93: 12467-12472.

Scharf, J. M., D. Damron, A. Frisella, S. Bruno, A. H. Beggs, L. M. Kunkel, and W. F. Dietrich, 1996 "The Mouse Region Syntenic for Human Spinal Muscular Atrophy Lies Within the *Lgn1* Critical Interval and Contains Multiple Copies of *Naip* exon 5." **Genomics**, 38: 405-417.

Güler, M., J. D. Gorham, C. S. Hsieh, A. Mackey, R. G. Steen, W. F. Dietrich, and K. M.

Murphy, 1996 "Genetic susceptibility to Leishmania: IL-12 responsiveness in T_H1 cell development." *Science*, 271: 984-987.

Dietrich, W. F., Miller, J., Steen, R., Merchant, M. A., Damron-Boles, D., Husain, Z., Dredge, R., Daly, M. J., Ingalls, K. A., O'Connor, T. J., Evans, C. A., DeAngelis, M. M., Levinson, D. M., Kruglyak, L., Goodman, N., Copeland, N. G., Jenkins, N. A., Hawkins, T. L., Stein, L., Page D. C., & Lander E. S., 1996 "A comprehensive genetic map of the mouse genome" *Nature*, 380: 149-152.

Parangi, S., W. Dietrich, G. Christofori, E. S. Lander, and D. Hanahan, 1995 "Tumor Suppressor Loci on Mouse Chromosomes 9 and 16 are Lost at Distinct Stages of Tumorigenesis in a Transgenic Model of Islet Cell Carcinoma" *Cancer Res.*, 55: 6071-6076.

Frankel, W. N., A. Valenzuela, C. M. Lutz, E. W. Johnson, W. F. Dietrich, and J. M. Coffin, 1995 "New Seizure Frequency QTL and the Complex Genetics of Epilepsy in EL Mice" *Mamm. Gen.*, 6: 830-838.

Dietrich, W. F., D. M. Damron, R. R. Isberg, E. S. Lander, and M. S. Swanson, 1995 "*Lgn1*, a Gene that Determines Susceptibility to *Legionella pneumophila*, Maps to Mouse Chromosome 13" *Genomics*, 26: 443-450.

Hegi, M. E., T. R. Devereaux, W. F. Dietrich, C. J. Cochran, E. S. Lander, J. F. Foley, R. R. Maronpot, M. W. Anderson, and R. W. Wiseman, 1994 "Allelotype Analysis of Mouse Lung Carcinomas Reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation" *Cancer Res.*, 54: 6257-6264.

Dietrich, W. F., E. H. Radany, J. S. Smith, D. Hanahan, J. M. Bishop, and E. S. Lander, 1994 "Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16" *Proc. Natl. Acad. Sci. USA*, 91: 9451-9455.

Dietrich, W. F., J. C. Miller, R. G. Steen, M. Merchant, D. Damron, R. Nahf, D. C. Joyce, M. Wessel, R. D. Dredge, A. Marquis, L. D. Stein, N. Goodman, D. C. Page, and E. S. Lander, 1994 "A Genetic Map of the Mouse with 4006 Simple Sequence Length Polymorphisms" *Nature Genetics*, 7: 220-245.

Wiseman, R. W., C. Cochran, W. Dietrich, E. S. Lander, and P. Söderkvist, 1994 "Allelotyping of Butadiene-Induced Lung and Mammary Adenocarcinomas of B6C3F1 Mice: Frequent Losses of Heterozygosity in Regions Homologous to Human Tumor Suppressor Genes" *Proc. Natl. Acad. Sci. USA*, 91: 3759-3763.

Metallinos, D. L., A. J. Oppenheimer, E. M. Rinchik, L. B. Russell, W. Dietrich, and S. M. Tilghman, 1994 "Fine Structure Mapping and Deletion Analysis of the Murine *piebald* Locus" *Genetics*, 136: 217-223.

Luongo, C., K. A. Gould, L. K. Su, K. W. Kinzler, B. Vogelstein, W. Dietrich, E. S. Lander, and A. R. Moser, 1993 "Mapping of Multiple Intestinal Neoplasia (*Min*) to Proximal Chromosome 18 of the Mouse" *Genomics* 15: 3-8.

Copeland, N. G., D. J. Gilbert, N. A. Jenkins, J. H. Nadeau, J. T. Eppig, L. J. Maltais, J. C. Miller, W. F. Dietrich, R. G. Steen, S. E. Lincoln, A. Weaver, D. C. Joyce, M. Merchant, M. Wessel, H. Katz, L. D. Stein, M. P. Reeve, M. J. Daly, R. D. Dredge, A. Marquis, N. Goodman, and E. S. Lander, 1993 "Genome Maps IV: The Mouse" *Science* 262: 67-82.

Copeland, N. G., N. A. Jenkins, D. J. Gilbert, J. T. Eppig, L. J. Maltais, J. C. Miller, W. F. Dietrich, A. Weaver, S. E. Lincoln, R. G. Steen, L. D. Stein, J. H. Nadeau, and E. S. Lander, 1993 "A Genetic Linkage Map of the Mouse: Current Applications and Future Prospects" *Science* 262: 57-66.

Dietrich, W. F., E. S. Lander, J. S. Smith, A. R. Moser, K. A. Gould, C. Luongo, N. Borenstein, and W. Dove, 1993 "Genetic Identification of *Mom-1*, a Major Modifier Locus Affecting *Min*-Induced Intestinal Neoplasia in the Mouse" *Cell* 75: 631-639.

Groot, P. C., C. J. A. Moen, W. Dietrich, J. P. Stoye, E. S. Lander, and P. Demant, 1992 "The recombinant congenic strains for analysis of multigenic traits: Genetic composition" *Faseb J.* 6: 2826-2835.

Dietrich, W., H. Katz, S. E. Lincoln, H.-S. Shin, J. Friedman, N. C. Dracopoli, and E. S. Lander, 1992 "A genetic map of the mouse suitable for typing intraspecific crosses" *Genetics* 131: 423-447.

Review Articles/Book Chapters/Technical Reports

Boyartchuk, V., and W. Dietrich. 2002 "Genetic dissection of host immune response." *Genes and Immunity* 3: 119-122.

Dietrich, W. F. 2001 "The origin and implications of the human genome project.", *Natl. Catholic Bioethics Quarterly* 1: 489-495.

Dietrich, W. F. 2001 "Using Mouse Genetics to Understand Infectious Disease Pathogenesis.", *Genome Res.* 11: 325-331.

Broman, K. W., V. L. Boyartchuk, and W. F. Dietrich. 2000 "Mapping time-to-death quantitative trait loci in a mouse cross with high survival rates." *Technical Report MS00-04*, Johns Hopkins University.

Dietrich, W. F., J. L. Weber, D. A. Nickerson, and P. Y. Kwok, 1999 "Identification and Analysis of DNA Polymorphisms", pp. 135-186 in *Genome Analysis Manual*, v.4, 1st edition, Birren, Green, and Myers, eds. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Guler M. L., Gorham J. D., Dietrich W. F., Steen R. G., Parvin C., Fenoglio D., Grupe A., Peltz G., and Murphy K. M., 1999 "Loci influencing development of Th responses. Identification from in vitro analysis." *Microbes Infect.*, 1: 79-88.

Dietrich, W. 1997. "Contagious Interest in Genetics." *Trends Genet.* 13: 50-51.

Miller, J. C., W. F. Dietrich, R. G. Steen, D. C. Joyce, M. A. Merchant, M. T. Wessel, D. M. Damron, R. W. Nahf, L. D. Stein, R. D. Dredge, A. L. Marquis, M. J. Daly, M. P. Reeve, N. Goodman, C. J. Lord, C. T. Montague, J.-B. Prins, J. A. Todd, and E. S. Lander, 1996 "SSLP/Microsatellite Genetic Linkage Map of the Mouse" in *Genetic Variants and Strains of the Laboratory Mouse*, 3rd edition. M. F. Lyon, S. Rastan, and S.D.M. Brown, eds. Oxford University Press, Oxford, U. K.

Dietrich, W.F., Copeland, N. G., Gilbert, D. J., Miller, J. C., Jenkins, N. A., and Lander, E. S., 1995 "Mapping the mouse genome: Current status and future prospects" *Proc. Natl. Acad. Sci. USA*, 92:10849-10853.

Dietrich, W., J. Miller, H. Katz, D. Joyce, R. Steen, S. Lincoln, M. Daly, M. P. Reeve, A. Weaver, P. Anagnostopoulos, N. Goodman, N. Dracopoli, and E. S. Lander, 1993 "SSLP Genetic Map of the Mouse (*Mus musculus*) 2N=40, July 1992", pp. 4.110-4.142 in *Genetic Maps- Locus Maps of Complex Organisms*, 6th ed. S. J. O'Brien, ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Patents

Cong, F., W. Dietrich, N. George, D. Liu, A. Schachter, A. Soni, and J. Zhou. "Compositions and methods for antibodies targeting BMP6." 2018. US 9862764.

CITY OF NEWTON

DOCKET REQUEST FORM

DEADLINE NOTICE: Council Rules require items to be docketed with the Clerk of the Council NO LATER THAN 7:45 P.M. ON THE MONDAY PRIOR TO A FULL COUNCIL MEETING.

To: Clerk of the City Council

Date: 03/13/2020

From (Docketer): Councilor Albright

Address: _____

Phone: _____

E-mail: _____

Additional sponsors: _____

1. Please docket the following item (it will be edited for length if necessary):

Requesting the reappointment of Gary du Moulin, 24 Myerson Lane, Newton Centre, to the Biosafety Committee.

RECEIVED
2020 MAR 13 PM 2:45
CITY CLERK
NEWTON, MA. 02459

2. The purpose and intended outcome of this item is:

- | | |
|--|--|
| <input type="checkbox"/> Fact-finding & discussion | <input type="checkbox"/> Ordinance change |
| <input type="checkbox"/> Appropriation, transfer, | <input type="checkbox"/> Resolution |
| <input type="checkbox"/> Expenditure, or bond authorization | <input type="checkbox"/> License or renewal |
| <input type="checkbox"/> Special permit, site plan approval, | <input checked="" type="checkbox"/> Appointment confirmation |
| <input type="checkbox"/> Zone change (public hearing required) | <input type="checkbox"/> Other: _____ |

3. I recommend that this item be assigned to the following committees:

- | | | |
|---|--|--|
| <input checked="" type="checkbox"/> Programs & Services | <input type="checkbox"/> Finance | <input type="checkbox"/> Real Property |
| <input type="checkbox"/> Zoning & Planning | <input type="checkbox"/> Public Safety | <input type="checkbox"/> Special Committee |
| <input type="checkbox"/> Public Facilities | <input type="checkbox"/> Land Use | <input type="checkbox"/> No Opinion |

4. This item should be taken up in committee:

Immediately (Emergency only, please). Please state nature of emergency:

- As soon as possible, preferably within a month
- In due course, at discretion of Committee Chair
- When certain materials are made available, as noted in 7 & 8 on reverse
- Following public hearing

5. I estimate that consideration of this item will require approximately:

- One half hour or less
- More than one hour
- More than one meeting
- Up to one hour
- An entire meeting
- Extended deliberation by subcommittee

6. The following people should be notified and asked to attend deliberations on this item. (Please check those with whom you have already discussed the issue, especially relevant Department Heads):

City personnel

Citizens (include telephone numbers/email please)

- _____
- _____
- _____
- _____
- _____

- _____
- _____
- _____
- _____
- _____

7. The following background materials and/or drafts should be obtained or prepared by the Clerk's office prior to scheduling this item for discussion:

8. I have or intend to provide additional materials and/or undertake the following research independently prior to scheduling the item for discussion. *

(*Note to docketer: Please provide any additional materials beyond the foregoing to the Clerk's office by 2 p.m. on Friday before the upcoming Committee meeting when the item is scheduled to be discussed so that Councilors have a chance to review all relevant materials before a scheduled discussion.)

Please check the following:

- 9. I would like to discuss this item with the Chairman before any decision is made on how and when to proceed.
- 10. I would like the Clerk's office to contact me to confirm that this item has been docketed. My daytime phone number is:
- 11. I would like the Clerk's office to notify me when the Chairman has scheduled the item for discussion.

Thank you.

Councilor Albright
Signature of person docketing the item

[Please retain a copy for your own records]

Application Form

Profile

Gary C. du Moulin
First Name Middle Initial Last Name

[Redacted]
Email Address

24 Myerson Lane
Home Address Suite or Apt

Newton Centre MA 02459
City State Postal Code

What Ward do you live in?

[X] Ward 8

[Redacted] [Redacted]
Primary Phone Alternate Phone

Retired Vice President of Quality Operations
Employer Job Title

Which Boards would you like to apply for?

Biosafety Committee: Submitted

Interests & Experiences

Please tell us about yourself and why you want to serve.

Why are you interested in serving on a board or commission?

For the past 30 years I have worked in the areas of cell and gene therapy (Cellcor, Sanofi-Genzyme). Prior to my industrial experience I was on the Harvard Medical school as a research scientist for 15 years. I have more than 150 publications in the areas of microbiology, epidemiology, and the regulation and quality control of living cells as a therapeutic modality. I am a graduate of Newton High School and wish to continue my service with the City of Newton.

G_DUMOULIN_RESUME_2019.docx
Upload a Resume

CURRICULUM VITAE

NAME Gary Carl du Moulin
ADDRESS 24 Myerson Lane, Newton Centre, MA

DATE OF BIRTH [REDACTED]

PLACE OF BIRTH [REDACTED]

EDUCATION

1969 B.S., Norwich University, Northfield, Vermont
1971 M.S., Northeastern University, Boston, Massachusetts
1980 M.P.H., School of Public Health, Boston University School
of Medicine, Boston, Massachusetts
1982 Graduate, The Command and General Staff College,
Ft Leavenworth, Kansas
1984 Ph.D., Boston University School of Medicine,
Division of Graduate Medical Sciences, Boston, MA
(Title of Dissertation: "The Pathophysiology of Gram
Negative Bacillary Sepsis: Multi-organ Responses to
Bacteremic Challenge in a Rat Model of Peritonitis")

LICENSURE AND CERTIFICATION

1973 Registered Microbiologist, American
Academy of Microbiology, License #937
1990 Director, Laboratory of Cellular Immunology and Cancer
Diagnosis, U.S. Dept of Health and Human Services
License #20-1150

- 1992 Regulatory Affairs Certified - Regulatory Affairs
Professional Society - Certificate #562
- 2001 Tissue Bank Director, Genzyme Biosurgery
ID No. CP097TP019, New York State Department of Health

ACADEMIC APPOINTMENTS

- 1976-1984 Associate in Anesthesia, Harvard Medical School,
Boston, Massachusetts
- 1984-1985 Instructor in Anesthesia, Harvard Medical School,
Boston, Massachusetts
- 1985-1989 Assistant Professor of Anesthesia, Harvard Medical
School, Boston, Massachusetts
- 1990-1991 Adjunct Professor of Chemical Engineering and
Senior Research Fellow, Center for Biotechnology Engineering,
Northeastern University, Boston, Massachusetts
- 2013-2017 Adjunct Associate Professor of Drug Regulatory Affairs
Massachusetts College of Pharmacy and Health Sciences University
Boston, Massachusetts

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES

- 1971- 1973 Captain, U.S. Army, Chief of Microbiology, Womack
Army Hospital, Fort Bragg, North Carolina
- 1978 - 1989 Director, Anesthesia/Respiratory Therapy Equipment
Assessment Unit, Beth Israel Hospital, Boston, MA
- 1989 - 1993 Commanding Officer (Colonel), 399th Combat Support Hospital,
U.S. Army Reserve
- 1993 - 1997 Chief of Staff (Colonel), 804th Medical Brigade,
U.S. Army Reserve

PRINCIPAL INDUSTRIAL RESPONSIBILITIES

- 1989-1992 Director, Quality Assurance / Quality Control,
Cellcor Inc. Newton, MA

1992-1995	Vice President, Quality Assurance / Quality Control, Cellcor Inc. Newton, MA
1995-1997	Director, Quality Systems Genzyme Tissue Repair Inc., Cambridge, MA
1997- 2000	Senior Director, Quality Systems Genzyme Tissue Repair Inc., Cambridge, MA
2000- 2007	Vice President, Quality Operations Genzyme Biosurgery, Cambridge, MA
2007 – 2014	Senior Director Quality, Aseptic Controls Genzyme (A Sanofi Co), Allston, MA

OTHER PROFESSIONAL POSITIONS

1972-1973	Microbiologist, Venereal Disease Screening Program, North Carolina Department of Public Health
1973-1976	Research Assistant, Harvard Medical School at the Beth Israel Hospital, Boston, Massachusetts
1977-1982	Major, 323rd Medical Laboratory, U.S. Army Reserve
1980	Faculty, American Society of Anesthesiologists Regional Workshop in Hazards and Pitfalls of Anesthesia Equipment, Chicago, Illinois
1980	Faculty, New York State Society of Anesthesiologists' 34th Postgraduate Assembly on Anesthesia Technology, New York
1980	Consultant, Tuberculosis Control Division, State of Massachusetts (Epidemiologic investigation of non-tuberculous mycobacterial Disease in the State of Massachusetts)
1981	Panel Member, U.S. Environmental Protection Agency Peer Review Workshop in Microbial Contamination of Water Arlie House, Virginia
1982-1986	Lieutenant Colonel, Executive Officer, 323rd Medical Laboratory, U.S. Army Reserve
1985	National Councillor, Northeast Branch, American Society for Microbiology
1985-1986	Vice President, Northeast Branch, American Society for Microbiology
1986-1988	President, Northeast Branch, American Society for Microbiology
1986-1989	Commanding Officer, 323rd Medical Laboratory, U.S. Army Reserve
1986	Faculty, "AIDS in the Hospital, Home, and Community,

1987	Advances in Care and Challenges for 1987" Boston, MA
1988	Promoted to Colonel, Medical Service Corps, U.S. Army Faculty, "International Symposium on Nosocomial Pneumonia, Nosocomial Infection Control in Intensive Care" Freiberg, Germany
1988	Faculty, "Waterborne Disease Agents and the Immuno- compromised - A Public Health Issue?" American Public Health Association Annual Meeting, Boston, MA
1991	Faculty, International Conference on Nosocomial Infection Control in Intensive Care, Freiberg, Germany

AWARDS AND HONORS

1969-1971	Northeastern University Tuition Assistantship, Department of Biology, Northeastern University, Boston, MA
1970	Phi Sigma Honor Society for Biological Research, Northeastern University
1973	Army Commendation Medal
1983	Army Achievement Medal
1987	Board of Fellows, Norwich University, Northfield, VT
1989	Army Commendation Medal with Oak Leaf Cluster
1990	Army Commendation Medal with 2nd Oak Leaf Cluster
1990	Meritorious Service Medal
1992	Expert Field Medical Badge
1993	Meritorious Service Medal with Oak Leaf Cluster
1998	Meritorious Service Medal with 2nd Oak Leaf Cluster
2000	Legion of Merit

MAJOR COMMITTEE ASSIGNMENTS

1972-1973	Infection Control Committee, Womack Army Hospital, Fort Bragg, NC
1977-1989	Committee on Infection, Beth Israel Hospital, Boston, MA,
1979-1989	Hospital Safety Committee (chairman), Beth Israel Hospital Boston, MA
1981-1982	Committee on Quality Assurance and Risk Management, Beth Israel Hospital, Boston, MA
1991-1998	Industrial Advisory Board, Dept. of Biology, Northeastern University
1997-2000	Advisory Panel on Gene and Cell Therapies, United States Pharmacopeia, Rockville, MD
1998-2000	Editorial Board - <i>Biologics - Regulatory Affairs Focus</i>

2000-2002	Chairman, Editorial Board- <i>Regulatory Affairs Focus</i>
2000-present	Gene Therapy, Cell Therapy, and Tissue Engineering Expert Committee United States Pharmacopeia
2006-present	Chairman, Ad hoc Subcommittee on Fetal Bovine Serum, United States Pharmacopeia
2008-present	Editorial Advisory Board – <i>Regenerative Medicine</i>
2009-present	Alternate Member, Scientific and Medical Research Funding Working Group California Institute for Regenerative Medicine (CIRM)

PROFESSIONAL SOCIETIES

1971	American Society for Microbiology
1973	American Academy of Microbiology
1977	New York Academy of Sciences
1977	Society of Armed Forces Medical Laboratory Scientists
1981	American Association for the Advancement of Science
1986	American Association of Pathologists
1989	American Society for Quality Control
1989	Regulatory Affairs Professional Society
1992	Cell Transplant Society
1992	Association of Military Surgeons of the United States
2010	Parenteral Drug Association

TEACHING EXPERIENCE

1976-1977	Lecturer, Department of Infectious Diseases, Children's Hospital Medical Center, Boston, MA
1976-1978	Lecturer, College of Pharmacy and Allied Health Professions, Northeastern University, Boston, MA
1976-1989	Lecturer, Department of Anesthesia, Beth Israel Hospital, Boston, MA
1977-1989	Lecturer, Department of Microbiology, Boston University School of Medicine
1985-1989	Assistant Professor of Anesthesia, Harvard Medical School, Boston, Massachusetts
2000- 2003	Lecturer, Health Professions and Sciences Program, Northeastern University, Boston, MA
2013-2017	Adjunct Associate Professor of Drug Regulatory Affairs Massachusetts College of Pharmacy and Health Sciences University Boston, Massachusetts

PATENTS

Inventors: du Moulin GC, Hedley-Whyte J, Lynch SE
 Invention: CA 1114271 - Assay of Gram-Negative Bacteria
 Country: Canada
 Issued: Dec 15, 1981
 Patent owner: President and Fellows of Harvard College

ORIGINAL REPORTS

1. Klick JM, du Moulin GC, Hedley-Whyte J, Teres, D, Bushnell LS, Feingold, DS: Prevention of Gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. *J. Clin. Invest.* 1975; 55:514-519.
2. Feeley TW, du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS: Aerosol polymyxin and pneumonia in seriously ill patients. *New Eng. J. Med.* 1975; 293:471-475.
3. Eichhorn JH, Bancroft ML, Laasberg LH, du Moulin GC, Saubermann AJ: Contamination of medical gas and water pipelines in a new hospital building. *Anesthesiology.* 1977; 46:286-289.
4. du Moulin GC, Saubermann AJ: The anesthesia machine and circle system are not likely to be sources of bacterial contamination. *Anesthesiology.* 1977; 47:353-358.
5. Klick JM, du Moulin GC: An oxygen analyzer as a source of *Pseudomonas*. *Anesthesiology.* 1978; 49:80-81.
6. du Moulin GC, Stottmeier KD: Use of cetyl-pyridinium chloride in the decontamination of water for culture of mycobacteria. *Appl. Env. Microbiol.* 1978; 36:771-773.
7. du Moulin GC, Dasse P, Miller MC, Friedland G: Staphylococcal outbreak in an intensive care unit: A narrative account of its management. *Heart and Lung.* 1979; 8:94-99.
8. du Moulin GC: Airway colonization by *Flavobacterium* in an intensive care unit. *J. Clin. Microbiol.* 1979;10:155-160.
9. Bancroft ML, du Moulin GC, Hedley-Whyte J: Hazards of hospital bulk oxygen delivery systems. *Anesthesiology.* 1980; 52:504-510. (reprinted In *Respiratory Care* 1981; 26:339-346.)

10. du Moulin GC, Doyle GO, MacKay J, Hedley-Whyte J: Bacterial fouling by of a hospital closed loop cooling system by *Pseudomonas* sp. *J. Clin. Microbiol.* 1981; 13:1060-1065.
11. du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A: Aspiration of gastric bacteria in antacid - treated patients: A frequent cause of postoperative colonization of the airway. *Lancet.* 1982; 1:242-245.
12. Fleischman RW, du Moulin GC, Esber HJ, Ilievski V, Bogden AE: Nontuberculous mycobacterial infection in two Rhesus monkeys due to *Mycobacterium intracellulare* serotype 10. *J. Am. Vet. Med. Assoc.* 1982; 181:1358-1362.
13. du Moulin GC, Lynch SE, Hedley-Whyte J, Broitman SA: Detection of Gram-negative bacteremia by *Limulus* ameocyte lysate assay: Evaluation in a rat model of peritonitis. *J. Infect. Dis.* 1985;151:148-152.
14. du Moulin GC, Paterson D, Hedley-Whyte J, Broitman SA: *E. coli* peritonitis and bacteremia cause increased blood-brain barrier permeability. *Brain Research.* 1985;340:261-268.
15. du Moulin GC, Sherman IH, Hoaglin DC, Stottmeier, KD: *Mycobacterium avium* complex: An emerging pathogen in Massachusetts. *J. Clin. Microbiol.* 1985;22: 9-12.
16. du Moulin GC, Skea, WM, Bartolini, BA: Microbiologic assessment of drinking water potability during brigade operations. *Milit. Med.* 1986;151:570-573.
17. du Moulin GC, Coleman EC, Hedley-Whyte J: Bacterial colonization and endotoxin content of a new renal dialysis water system composed of acrylonitrile butadiene styrene. *Appl. Environ. Microbiol.* 1987;53: 1322-1326.
18. Doos WG, du Moulin GC, Jordi H, Orf HW, Seder R, Skea WM: Field tests on four state-of-the-art blood chemistry analyzers in a mobile laboratory setting. *Milit. Med.* 1988;153: 81-86.
19. Pelletier PA, du Moulin GC, Stottmeier KD: Mycobacteria in public water supplies: Comparative resistance to chlorine. *Microbiol. Sci.* 1988; 5:147-148.
20. du Moulin GC, Pelletier PA, Stottmeier KD, Tsang AY, Hedley-Whyte J: Concentration of *Mycobacterium avium* by hospital hot water systems. *JAMA* 1988; 260:1599-1601.

21. du Moulin GC, Asiaf JR, Cesaro P, Prewandowski KA, Silva CV, McKeon MM, Koblitz KA; Field evaluations of the Testuria and Selecticult systems for the in vitro screening of bacteriuria. *J. Military Medical Laboratory Science*; 1991; 19:196-198.
22. Pelletier PA, Carney EM, du Moulin GC: Comparative resistance of *Mycobacterium avium* complex and other nontuberculous mycobacteria to chloramine. *Proceedings of the Annual Meeting of the American Water Works Association*. June 1991.
23. du Moulin GC, Hamilton DL, Price JE, Kosik ZJ, Liu VYS, Osband ME: Quality assurance and quality control (QA/QC) in Biocare. Autolymphocyte Therapy as a model. *Biopharm* 1990; 3:30-35.
24. du Moulin GC, Price JE, Shen YJ, Osband ME: Use of the *Limulus* amoebocyte lysate assay (LAL) assay in Living Cell Therapies. *Biopharm* 1992; 5:32-37.
25. du Moulin GC, Liu V, Osband ME: Implementation of an effective program for Quality Assurance and Quality Control in Living Cell Therapies: A two year experience with Autolymphocyte Therapy. *Transplantation Proceedings* 1993; 24:2803-2808.
26. du Moulin GC, Stack J, Kruger R, Liu V: Quality Assurance/Quality Control Compliance Program: A Cellular Therapy Developer's Perspective. *Regulatory Affairs* 1993; 5:461-472.
27. du Moulin GC, Stack J, Pitkin Z, et al.: A Review of the Development and Implementation of a model QA/QC System Supporting the Multisite Delivery of a Lymphocyte Based Therapy for Renal Cell Carcinoma: A Three Year Experience. *Biotech Bioengineer* 1994; 43:693-699.
28. Hamilton D, Goodwin, J, Clarke M, du Moulin, G, et al.: Preliminary Validation of an activation assay for *ex vivo* activated T cells utilized in cancer immunotherapy. *Biotech Bioengineer* 1994; 43:700-705.
29. du Moulin GC, Pitkin Z, Shen, Y, et al.: Overview of a Quality Assurance/Quality Control Compliance Program Consistent with FDA Regulations and Policies for Somatic Cell and Gene Therapies: A Four Year Experience. *Cytotechnology* 1994 15:365-372.
30. Montecalvo MA, Forseter G, Tsang AY, du Moulin GC, Wormser GP: Colonisation of potable water with *Mycobacterium avium* complex in homes of HIV-infected patients. *Lancet* 1994; 313:1639-1640 (letter).

31. Slavin, JD, du Moulin GC, Borden, S, Tabaroni, R, DeProspero, D: Hospital Integrated Lanes Training (HILT): Brigade Directed Implementation of a Medical Lanes Training Program During Annual Training. *Milit. Med.* 1994;159:704-708.
32. du Moulin GC, Haggerty N, Parker WA, Humphrey JC, Tabaroni RF, Slavin JD: Experiences with Extended Duration Medical Laboratory Support in Deployable Medical Systems. *Milit. Med.* 1996; 161: 521-525.
33. Pitkin, Z, Chhugani P, Chenette A, Shen Y, du Moulin GC: Validation of an Automated Method of Endotoxin Testing for Use in the end product testing of *ex vivo* Activated T-lymphocytes used in a Somatic Cell Therapy. *Biotech and Bioengineer.* 1996;50:541-547.
34. Morohashi M, du Moulin GC, Barone L, Mayer GL: A Case Report on Industrialization of Autologous Chondrocyte Implantation in the United States. *Biopharmacology.* 1997 ;23:568-571.
35. Mayhew T, Williams GR, Senica MA, Kuniholm G, du Moulin GC: Validation of a Quality Assurance Program for Autologous Cultured Chondrocyte Implantation. *Tissue Engineering* 1998; 4:325-334.
36. du Moulin, GC and Morohashi, M: Development of a regulatory strategy for the cellular therapies: An American perspective. *Materials Science and Engineering* 2000; C13:15-17.
37. du Moulin, GC. Some final thoughts. *Regulatory Affairs Focus* 2002; 7:40.
38. du Moulin GC, Entstrasser, CA, Kielpinski GL: Challenges of quality assurance and product release in patient specific technologies. *Regulatory Affairs Focus* 2004; 9:40-42.
39. Kielpinski G, Prinzi S, Duguid J, Price, du Moulin G. Validation of a automated sterility test method for release of autologous cultured chondrocytes for implantation. *Cytotherapy* 2005: 7:531-541.
40. Duguid J, du Moulin G. Automated rapid microbiological methods for the biopharmaceutical industry : Selection, validation and implementation for an autologous cell therapy product. *Am. Pharm Rev.* 2009: 74-77.
41. Duguid J, Kielpinski G, Seymour B, du Moulin G. Risk assessment for a rapid mycoplasma test optimized for cell therapy products. *Am Pharm Rev.* 2009:100-104.

REVIEWS

1. du Moulin GC, Hedley-Whyte J: A plea for moderation in anesthesia standards. *AORN Journal*. 1977; 25:1025-1028.
2. du Moulin GC, O'Brien AP: Pulmonary tuberculosis in surgical patients. *Survey of Anesthesiology*. 1978; 22:590-591.
3. du Moulin GC, Hedley-Whyte J: Bacterial interactions between anesthesiologists, their patients, and equipment. *Anesthesiology*. 1982; 57:37-41.
4. Hedley-Whyte J, du Moulin GC: The environment of endotracheal tubes in the colonization of the upper airway and development of pneumonia. *Proc. Workshop on Tracheal Tubes*, HFK 310, Bureau of Medical Devices (RC Shupak and TC Deas, eds.), Silver Spring, Department of Health and Human Services. 1982; 91-102.
5. du Moulin GC, Hedley-Whyte J: The stomach as a bacterial reservoir; clinical significance. *Int. Med. for the Specialist*. 1982; 3:47-55.
6. du Moulin GC, Hedley-Whyte J: Hospital-associated viral infection and the anesthesiologist. *Anesthesiology*. 1982; 59:51-65.
7. Bancroft ML, du Moulin GC: Re-evaluating the role of respiratory care equipment and practices in the prevention of nosocomial pneumonia. *Resp. Care*. 1983; 28:165-168.
8. du Moulin GC, Paterson D: The clinical relevance of post mortem microbiologic examination: A review. *Human Pathol.* 1985;16: 539-548.
9. du Moulin GC, Stottmeier KD: Waterborne mycobacteria: An increasing threat to health. *ASM News* 1986;52: 525-529.
10. du Moulin GC, Love W: The value of autopsy microbiology. *Clin. Microbiol. Newsl.* 1988; 10:165-167.
11. du Moulin GC: Minimizing the potential for nosocomial pneumonia: Architectural, engineering, and environmental considerations for the intensive care unit. *Eur. J. Clin. Microbiol.* 1989; 8:69-74.
12. du Moulin GC: Tracheobronchial colonization. *Klin. Wochenschr.* 1991; (Suppl XXVII) 69:6-11.
13. Janoschek R, du Moulin GC: Ultraviolet Disinfection in Biotechnology: Myth vs. Practice. *Biopharm* 1994; 7: 24-31.

14. Ostrovski S, du Moulin GC: Achieving Compliance in Validation and Metrology for Gene and Cell Therapy. *Biopharm* 1995; 8:20-28.
15. Kielpinski G, Kehinde O, Kaplan B, Bonn T, Buxton D, Wescott M., Arangio A, Duguid J, Thyne, C, du Moulin, GC: Quality Control for *ex vivo* Cell Therapy. *Biopharm* 1997; 10:34-40.
16. Omstead D, Baird L, Christenson L, du Moulin G, Tubo R, Maxted D, Davis J, Gentile F: Voluntary Guidance for the Development of Tissue-Engineered Products. *Tissue Engineering* 1998; 4:239-266.
17. du Moulin GC: The potential and challenges of tissue engineering activities in the United States. International Technology Research Institute Workshop on Tissue Engineering Research in the United States. June, 2000.
18. Sentissi A, du Moulin GC: Quality systems for xenotransplantation products. *Regulatory Affairs Focus*, 2000; 35-40 (June).
19. du Moulin GC: The challenges and future of cell therapy and tissue regeneration. *Symposium Proceedings, BioJapan 2000*, 337-346.
20. du Moulin, GC: Cell therapy and tissue engineering: An overview. *Bioprocessing Journal* 2003;2:17-21.
21. Denoya CD, Colgan ST, du Moulin GC. Alternative microbiological methods in the pharmaceutical industry. The need for a new microbiology curriculum. *American Pharmaceutical Review* 2006; 9:10-18.
22. Duguid J, Balkovic, E, du Moulin GC. Rapid Microbiological Methods: Where are they now? *American Pharmaceutical Review* 2011; 13:18-25.

BOOKS AND MONOGRAPHS

1. du Moulin GC, Lynch SE, Hedley-Whyte J, Broitman SA: The detection of Gram-negative bacteria in the blood of septic rats by a *Limulus* amoebocyte lysate assay. In SW Watson, J Levin, TJ Novitsky (eds.), Detection of Bacterial Endotoxins with the *Limulus* Amoebocyte Lysate Test, Alan R. Liss, Inc., New York. *Prog. Clin. Biol. Res.* 1987; 231:349-356.

2. du Moulin GC: Minimizing the potential for infection in the hospitalized burned patient: Architectural, engineering, and environmental considerations. In Acute Management of Burn Trauma, JAJ Martyn (ed.), W.B. Saunders Company, Philadelphia, 1990.
3. du Moulin GC, Mayhew T, Kielpinski G, Citron M, Surgenor T: The Application of Good Manufacturing Practices (GMP) to the Expansion of Human Cell Populations for Cell and Tissue Therapy. in Animal Cell Technology: Basic and Applied Aspects (*Proceedings of the 8th Annual Meeting of the Japanese Association of Animal Cell Technology*). ed. Funatsu K, Shirai Y, Matsushita T, Kluwer Academic Publishers, Dordrecht, 8:19-23, 1997.
4. Schaeffer S, Stone BB, Wolfrum J, and du Moulin GC. "Ex vivo Autologous Cell Therapies" in Biopharmaceutical Process Validation ed. Sofer G, and Zabriskie, D.W., Marcel Dekker Inc. New York, 2000.
5. Expert Committee for Gene Therapy, Cell Therapy and Tissue Engineering. "<1046> Cell and Gene Therapy Products" (General Information Chapter).in United States Pharmacopeia-National Formulary 26, Rockville MD, US Pharmacopeial Convention, pp2257-2285, 2002.
6. du Moulin GC, "Adventitious Agents and Chemical Toxicity" in Methods of Tissue Engineering, ed. Atala, A and Lanza, R. Academic Press, San Diego, 2002.
7. du Moulin GC, Entstrasser CA, Kielpinski G. "Quality control in producing cells for tissue engineering". In Tissue Engineering in Musculoskeletal Clinical Practice. American Association of Orthopaedic Surgeons. Rosemont, IL, 2004.
8. Expert Committee for Gene Therapy, Cell Therapy and Tissue Engineering. "<1043> Ancillary Materials for Cell, Gene and Tissue Engineered Products" (General Information Chapter).in United States Pharmacopeia-National Formulary 29, Rockville MD, US Pharmacopeial Convention, pp.2814-2821, 2006.
9. du Moulin GC, Kielpinski G, Prinzi S, Duguid J, and Price A. "Detection of microbial contaminants for cell therapy products: Validation of an automated microbial detection system" in Encyclopedia of Rapid Microbiological Methods, ed. Miller M., Parenteral Drug Association, Bethesda, MD, pp273-290, 2005.
10. Expert Committee for Gene Therapy, Cell Therapy and Tissue Engineering. "<1024> Bovine Serum" (General Information Chapter). Pharmacopeial Forum 35(3) 629-647, 2009.

11. du Moulin GC. "Approaches to validation for cellular therapy products. In Cellular Therapy: Principles, Methods, and Regulations. Ed. Areman EM and Loper K. American Association of Blood Banks. Bethesda, MD, 2009.
12. Expert Committee for Gene Therapy, Cell Therapy and Tissue Engineering. "<90> Fetal Bovine Serum – Quality Attributes and Functionality Tests. *Pharmacopeial Forum* 35(5) 1219-1224, 2009.
13. Houck T and du Moulin GC. "Approaches to validation for cellular therapy products. In Cellular Therapy: Principles, Methods, and Regulations. (2nd edition) Ed. Areman EM and Loper K. American Association of Blood Banks. Bethesda, MD, 2016.
14. Duguid J, Khuu H, and du Moulin GC. "Assessing cellular therapy products for microbial contaminants". In Cellular Therapy: Principles, Methods, and Regulations. (2nd edition) Ed. Areman EM and Loper K. American Association of Blood Banks. Bethesda, MD, 2016.
15. USP, Modern Microbiological Methods Expert Panel. The development of compendial rapid sterility tests (Stimuli to the Revision Process). *Pharmacopeial Forum*, Vol 46 (5), 2017.
16. du Moulin GC. Regenerative Medicine Advanced Therapies: Phase Appropriate Good Manufacturing Practices. In Phase Appropriate Good Manufacturing Practices for Biological Processes. Ed. Deeks T, Parenteral Drug Association, Bethesda, MD, pp 341-397, 2018.
17. Balkovic E and GC du Moulin. Competency based training approach for microbial identifications. In Microbiological Identifications: Vol 2, Ed. Reber D. and Griffin M, Parenteral Drug Association, Bethesda, MD, pp 457-492, 2018.

ABSTRACTS

1. Klick JM, du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS: Prevention of Gram-negative bacillary pneumonia with polymyxin B aerosol. *Crit. Care Med.* 1975; 3:38.
2. du Moulin GC, Lynch SE, Hedley-Whyte J: Utilization of the *Limulus* amebocyte lysate assay in the rapid diagnosis of Gram-negative bacteremia. *Fed. Proc.* 1978; 37:319.

3. du Moulin GC, Friedland G, Indorato K, Stottmeier KD: Contamination of mycobacterial specimens with a waterborne strain of *Mycobacterium avium*. Abstr. 78th Ann. Meeting Am. Soc. Microbiol., Washington, D.C. 1978; p.206.
4. du Moulin GC: Lower respiratory tract colonization of seriously ill patients by a waterborne strain of Flavobacterium. Abstr. 78th Ann. Meeting Am. Soc. Microbiol. Washington, D.C. 1978; p.285.
5. Dasse P, Boyle C, du Moulin GC, Stottmeier KD, Friedland G: Pseudoepidemic traced to contamination of clinical specimens by waterborne atypical mycobacteria. Abstr. Assoc. for Practitioners in Inf. Control, 1979 APIC Journal. 1979; 7:29-30.
6. du Moulin GC, Lynch SE, Bousquet FB III, Hedley-Whyte J: Inability to reproduce bacteremia in rats paralyzed and ventilated with nitrous oxide and oxygen. Fed. Proc. 1979; 38:1002.
7. du Moulin GC, Lynch SE, Chien, N, Hedley-Whyte J: Gram-negative bacteremia and the *Limulus* ameocyte lysate assay (LAL). Fed. Proc. 1980; 39:1178.
8. du Moulin GC, Doyle GO, MacKay J, Hedley-Whyte J: Biofouling by *Pseudomonas fluorescens* of a hospital closed loop cooling system. Abstr. 80th Ann. Meeting Am. Soc. Microbiol., Washington, DC. 1980; p. 179 (N94).
9. du Moulin, GC, Sherman IH, Stottmeier KD: *Mycobacterium intracellulare*; an emerging pathogen in Massachusetts. Abstr. 81st Ann. Meeting, Am. Soc. Microbiology, Washington, DC. 1981; p.269 (C43).
10. Somersille CS, du Moulin GC, Hedley-Whyte J: *E. coli* peritonitis after C3 depletion: sensitive assay of chemotactic behavior based on species differences. Fed. Proc. 1982; 41:325.
11. du Moulin GC, Merrill A, Sherman IH, Stottmeier KD: *M. avium-intracellulare* in Massachusetts. Abstr. 82nd Ann. Meeting, Am. Soc. Microbiology, Washington, DC. 1982; p.305 (C202).
12. du Moulin GC, Laasberg LH, Lynch SE, Hedley-Whyte J: Effect of naloxone and morphine on plasma leu and met enkephalin in rats with *E. coli* peritonitis. Fed. Proc. 1982; 42:301.
13. du Moulin GC, Jaciow D, Teres D, Stottmeier KD: Significance of respiratory isolates of *Mycobacterium avium-intracellulare* (MAIC). Abstr. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Am. Soc. Microbiology, Washington DC. 1983; p.278 (1048).

14. du Moulin GC, Paterson D, Hedley-Whyte J: *E.coli* peritonitis is a cause of increased blood-brain barrier permeability. *Fed. Proc.* 1984; 43:381.
15. du Moulin GC, Lynch SE, Hedley-Whyte J, Broitman SA: Reticuloendothelial clearance of radiolabeled *E. coli* in experimental peritonitis and bacteremia. *Abstr. 85th Ann. Meeting, Am. Soc. Microbiology*, Washington, DC. 1985; p.29 (B66).
16. du Moulin GC, Coleman EC, Hedley-Whyte J: Bacterial colonization and endotoxin content in a new renal dialysis water composed of acrylonitrile butadiene styrene (ABS). *Fed. Proc.* 1986; 45:639.
17. du Moulin GC, Skea WM, Bartolini BA: Microbiologic assessment of drinking water potability during brigade operations. *Abstr. 11th Ann. Meeting, Soc. Armed Forces Med. Lab. Scientists.* 1986; 15:18.
18. du Moulin GC, Coleman EC, Tsang AY, Stottmeier KD: Contamination of drinking water supplies with *Mycobacterium avium* complex (MAC). *Abstr. 26th Intersci. Conf. Antimicrobial Agents and Chemotherapy*, New Orleans, LA. 1986; p.297 (1101).
19. Pelletier PA, Gates SG, Carney EM, du Moulin GC: Comparative resistance of waterborne mycobacteria to chlorine. *Abstr. 87th Ann. Meeting Am. Soc. Microbiol.*, Atlanta, GA, 1987; p. 250 (N33).
20. Johnston LC, du Moulin GC: Microbial impact to public drinking water supplies by nonmigratory Canada geese. *Abstr. 87th Ann. Meeting, Am. Soc. Microbiol.*, Atlanta GA, 1987; p.249 (N29).
21. De Girolami PC, Tsang AY, du Moulin GC, Rose R, Sisson G, Stottmeier KD: Serovars of *Mycobacterium avium* complex isolated from patients with AIDS. *Abstr. 87th Ann. Meeting Am. Soc. Microbiol.*, Atlanta, GA, 1987; p.128 (V12).
22. Gates SG, du Moulin GC, Hindman B, Hedley-Whyte J: Survival of bacteria in anesthesia breathing circuits. *Fed. Proc.* 1987; 46:1303 (5755).
23. du Moulin GC, Skea WM: Contamination of a lake by sewage effluent caused by increased military activity. *Abstr. 12th Ann. Meeting, Soc. Armed Forces Med. Lab. Scientists.* 1987; 16:18.
24. Doos WG, Orf HW, Seder RH, Jordi H, Skea WM, du Moulin GC: Field trials of four chemistry analyzers. I. Mobile medical laboratory deployment. *Abstr. 12th Ann Meeting, Soc. Armed Forces Med. Lab. Scientists.* 1987; 16:15.

25. Orf HW, Seder RH, Doos WG, Jordi H, Skea WM, du Moulin GC: Field trials of four chemistry analyzers. II. Quantitative evaluation. *Abstr. 12th Ann. Meeting Soc. Armed Forces Med. Lab. Scientists* 1987; 16:21.
26. Seder RH, Doos WG, Orf HW, Jordi H, Skea WM, du Moulin GC: Field trials of four chemistry analyzers. III. Qualitative evaluation. *Abstr. 12th Ann. Meeting, Soc. Armed Forces Med. Lab. Scientists.* 1987; 16:22.
27. Pelletier PA, du Moulin GC: Comparative resistance of waterborne mycobacteria to chloramine. *Abstr. 88th Ann. Meeting, Am. Soc. Microbiol.* 1988; p.256 (N-71).
28. Pelletier PA, du Moulin GC, Stottmeier KD: Prevalence of mycobacteria in a renal dialysis water system. *Abstr. 88th Ann Meeting, Am. Soc. Microbiol.* 1988; p. 413 (L-12).
29. George DM, du Moulin GC, Carney EM: Comparative evaluation of a renal dialysis ultrapure water system using epifluorescence microscopy, R2A media, millipore SPC samplers, and LAL assay. *Abstr. 88th Annual meeting, Am. Soc. Microbiol.* 1988; p.413 (L-15).
30. Love W, MacHarrie D, Patton J, du Moulin GC: Assessment of the civilian contract training program for medical laboratory technicians in army reserve units. *Abstr. 13th Ann. Meeting, Soc. Armed Forces Med. Lab. Scientists.* 1988; 17:21.
31. Hindman B, Johnston L, du Moulin GC, Hedley-Whyte J: Transmission of bacterial aerosols from anesthesia machines. *Fed. Proc.* 1988; 2A1397 (Abstr. 6398).
32. du Moulin GC, Stottmeier KD, Pelletier PA, Hedley-Whyte J: Waterborne *Mycobacterium avium* is amplified by growth in hospital hot water systems. *Proc. International Congress Infect Dis.* 1988; p.197 (Abstr. 226).
33. du Moulin GC, Stottmeier KD, Pelletier PA: Health effects of mycobacteria in public water supplies. *Abstr. 116th Ann. Meeting, Am. Public Health Association.* 1988; p.118 (Abstr. 2034).
34. Duray PH, du Moulin GC, Boucher L, Splitz A: The cultivation of *Borrelia* in a mobile field laboratory. *Abstr. 14th Ann. Meeting Soc. Armed Forces Med. Lab. Scientists.* 1989;18:4.
35. du Moulin GC, Calhoun BH, Fisher SL, Duray PH: The field medical laboratory configured to investigate the epidemiology of Lyme borreliosis. Operational concepts and concerns. *Abstr. 14th Ann. Meeting Soc. Armed Forces Med. Lab. Scientists.* 1989;18:3.

36. du Moulin GC, Hamilton DL, Price JE, Osband ME: Quality assurance/quality control (QA/QC) issues in adoptive immunotherapy. *Abstr. Proc. 4th Ann. Conf. on Clinical Immunology* 1989. (Abstr #9).
37. Price JE, Shen YJ, du Moulin GC, Osband ME: Safe processing of autologous lymphocytes for therapeutic use: Use of the *Limulus* amebocyte lysate test for endotoxin testing. *Abstr. 90th Ann Meeting, Am Soc. Microbiol.* 1990.
38. Chow A, du Moulin GC: Demonstration of *in vitro* antimicrobial activity of *Schisandra chinensis* against strains of *Mycobacterium avium* isolated from environmental water sources and patients with AIDS. *Abstr. Proc. International Cong Infect. Disease.* 1990,pg 38 (abstract 527)
39. Koblitz KA, Arpin JA, Boulanger CD, du Moulin GC: Evaluation of a cold water procedure to clean and sanitize eating and kitchen utensils in a tactical field environment. *Abstr. Proc. 15th Ann. Meeting Soc. Armed Forces Med. Lab. Scientists.* 1990; 19:55 (P-15).
40. Wormser G, Forseter G, Montecalvo MA, Tsang AY, du Moulin GC: Recovery of *Mycobacterium avium* complex (MAC) from the home tap water of HIV-infected patients in New York State. *31st Interscience Conference on Antimicrobial Agents and Chemotherapy.* 1991,pg 38 (abstract 240).
41. du Moulin GC, Hamilton D, Oommen S, Osband ME: Development of an effective diagnostic laboratory program to support the adoptive immunotherapy of cancer. *Fed Proc* 1992; 6:2886.
42. du Moulin GC, Cyr C, Chew-Darke J, Pitkin Z, Stack J, Osband ME, Torres B: Intrinsic contamination by *Bacillus* in blood culture media: Implications for Quality Control in adoptive immunotherapy. *Proc 1992 Ann Meeting Am Soc Microbiol.*1992; 436 (C-95).
43. Eylath A, du Moulin GC, Cyr C, Pitkin Z, Shen Y, Liu V., Osband ME: Validation of the Isolator "Isostat" Microbial System for sterility testing of cells in adoptive immunotherapy. *Proc. 1992 Ann. Meeting Am. Soc. Microbiol.* 1992; 428 (C-48).
44. Borden S, du Moulin GC, Foehr D: Beyond Regional Training Sites: DEPMEDS training for Army medical personnel is enhanced when RTS equipment training is augmented at unit level by integration of the DOD DEPMEDS Clinical Treatment Policies and Data Base. *Soc Armed Forces Med Lab Scientists Proceed.* 1992; 21:50 (DS-8).

45. du Moulin GC, Hamilton D, Oommen, C. Osband ME: Development of an effective diagnostic laboratory program to support the adoptive immunotherapy of cancer. *Cell Transplantation* 1992; 1:107 (16).
46. du Moulin GC, Liu V, Eylath A, Cyr C, Pitkin Z, Shen YJ, Osband ME: Testing of living cells for sterility and endotoxin prior to patient infusion. *Cell Transplantation* 1992; 1:107 (17).
47. Ross SD, Liu V, du Moulin G, Osband ME: Challenges in performing clinical trials using living cell therapies. *Cell Transplantation* 1992; 1: 233 (256).
48. du Moulin GC, Borden S, Foehr D, Sullivan J, Paul C, DePriest O, Chabior L, Petrangelo J, Andrade L, Allison D, Martinez-Dickerson S: Hospital Integrated Lane Training (HILT): Review of initial implementation for a combat support hospital (CSH) during annual training. *J Milit. Med. Lab. Sci.* (22, 1993).
49. Borden S, Foehr D, du Moulin GC: Hospital Integrated Lane Training (HILT). *J. Milit. Med. Lab Sci.* (22, 1993).
50. du Moulin GC, Liu V, Chew-Darke J, Conti E, Cyr C, Peart J, Pitkin Z, Shen Y, Stack J, Hamilton D, Davies B, White A, and Osband ME: Implementation of an effective program for quality assurance and quality control in living cell therapies. A 2 year experience with autolymphocyte therapy. *Proc. Amer Chem Soc* (Abstract #120, 1993).
51. Clarke MB, du Moulin GC, Gaines D, Liu V: Validation of sterility testing media used in the autolymphocyte therapy of cancer: Application of Quanti-Cult System. *Proc 1993 Meeting Am Soc Microbiol* (Q276, 1993).
52. Miesowicz F, du Moulin GC, Liu V, Hamilton D, Davies B, Pitkin Z, Stack J, Chew-Darke J, and Osband ME: Development and Implementation of Delivery and Quality Control System for Cellular Therapies: Experience in 500 Patients. *Cell Transplantation* 1994;3:S53.
53. Cyr C, Pitkin Z, Shen Y, du Moulin GC: Evaluation of an Automated Method of Endotoxin Testing for Use in the End Product Testing of *ex vivo* Activated T-Lymphocytes Used in the Adoptive Immunotherapy of Cancer. *Proceedings of the Cell Transplant Society*:1994, 3:238 (108).
54. Pitkin Z, Cyr C, Shen Y, Perkins R, du Moulin GC. Quality Control Sterility Testing Program for *ex vivo* Activated Lymphocytes: Recovery of *Propionibacterium acnes* (*P. acnes*) From Apheresis Cell Product (ACP). *Proceedings of the Cell Transplant Society* :1994, 3:222 (46).
55. Pitkin Z, Chhugani P, Shen Y, Chennette A, du Moulin GC: Validation of an automated method of endotoxin testing for use in the end product testing of *ex*

vivo activated T lymphocytes used in the adoptive immunotherapy of cancer. *Proc 1995 Am Soc Microbiol.* (1995).

56. du Moulin GC, Mayhew T, Kielpinski G, Citron M, and Surgenor T: The application of Good Manufacturing Practices (GMP) to the Expansion of Human Cell Populations for Cell and Tissue Therapy. *Proc. Eighth Annual Meeting of the Japanese Association for Animal Cell Technology* (1995).

57. Mayhew T, du Moulin GC, Williams R, Garcia R, Entstrasser C, Peart J: Quality Assurance for Cells Manipulated *ex vivo* for Autologous Transplantation. *Proceedings of the 1996 Annual Meeting of the American Association of Tissue Banks.* (1996).

58. du Moulin GC : Aspects of Quality Control/Quality Assurance for Cell and Tissue Based Therapies. *Proceedings of the 1st Annual Meeting, Process Development and Production Issues for Cellular Therapy and Tissue Engineering - The Williamsburg BioProcessing Foundation* (1996).

59. Buxton D, Thyne C, Kielpinski G, Hendricks A, Buonopane M, Deshield N, and du Moulin GC: Initial Evaluation of the Difco ESP System for Use in Sterility Testing of *ex vivo* Cultured Autologous Chondrocytes for Transplantation. *Proceedings of the 97th General Meeting of the American Society for Microbiology* (1997).

60. Buxton D, Kielpinski G, Hendricks A, Deshield N, Prinzi S, Galvez G, Lessor J, Antohi M, Araneda M, Buonopane M, and du Moulin GC: Evaluation of Media in USP Sterility Testing of *ex vivo* Cultured Autologous Chondrocytes and Keratinocytes for Transplantation. *Proceedings of the 97th General Meeting of the American Society for Microbiology* (1997).

61. Buxton D, Kielpinski G, Hendricks A, Deshield N, Buonopane M, Prinzi S, Galvez G, Lessor J, Antohi M, Araneda M, Kehinde O, Thyne C, Hall A, and du Moulin GC: Management of Microbial Colonization of *ex vivo* Cultured Autologous Keratinocytes for Transplantation. *Proceedings of the 97th General Meeting of the American Society for Microbiology* (1997).

62. Mayhew T, Williams GR, Lang K, Senica M, Voelksen R, Entstrasser C, du Moulin GC: Quality Assurance for Cells and Tissues Cultured *ex vivo* for Autologous Transplantation. *1st Annual Smith and Nephew International Symposium - Advances in Tissue Engineering and Biomaterials*, University of York, England, (S5) 1997.

63. du Moulin GC, Mayhew T, McCormack S, Kielpinski G, R Voelksen: Development of a Quality Assurance Program for Autologous Chondrocyte Implantation Based Upon the Commission of the European Communities (EEC) "Guide to Good Manufacturing Practice for Medicinal Products". *Proceedings of the 7th Annual Meeting of the European Tissue Repair Society*, Cologne, Germany 1997.
64. du Moulin GC, Mayhew T, Williams R, Mc Cormack S, Senica M, Kuniholm G, Nowowieski P, Voelksen R: Evaluation of a Quality Assurance Program for Autologous Chondrocyte Implantation. *Proceedings of the 2nd European Tissue Repair Society Consensus Meeting* Freiberg, Germany 1997.
65. Wolfe L, and du Moulin G: Manufacturing and Quality Systems for Autologous Cultured Chondrocytes. *Proceedings of the Annual Meeting of the American Chemical Society*, Boston, 1998.
66. Macchi M, Bonn T, Wolfrum J, Roth M, Arangio A, Larson E, Fairweather B, Apostol G, Zheng R, DeFranzo B, du Moulin G, and Kielpinski G: Use of a Modified Biological Reactivity Test as a Lot Release Assay for Autologous Cultured Chondrocytes: An Alternative to the General Safety Test. *Proceedings of the Annual Meeting of the Parenteral Drug Association*, Washington, DC, 1998.
67. Peterson L, Surgenor T, Cummings J, du Moulin GC: Carticel Cell Therapy: From Research to the Market. *Abstr. 219th Meeting of the American Chemical Society*, San Francisco, CA, 2000.
68. du Moulin GC, Barone L, Resink M, Entstrasser C, Kielpinski G, Mc Cormack S: A Quality Assurance/Quality Control compliance program for autologous chondrocyte implantation: A 4,000 patient experience. *Abstrs. of the 3rd Annual Meeting*, International Cartilage Repair Society, Gothenberg, Sweden, 2000.
69. du Moulin GC, Entstrasser C, Kielpinski G, Barone L, McCormack S: A Quality Assurance/Quality Control compliance program for autologous chondrocyte implantation: A 3,600 patient experience. *Abstr. of the International Workshop on Bio-integrated Materials and Tissue Engineering*, Tsukuba, Japan, 2000.
70. du Moulin GC: Biologics (In Focus Department), *Regulatory Affairs Focus* (pg 2), June, 2000.
71. du Moulin GC: Quality Systems for autologous chondrocyte implantation: A 5,000 patient experience with Carticel. *Proceedings of the 2nd Symposium of Recent Advances in Cartilage Repair and Tissue Engineering*. Portoroz, Slovenia, 2001.
72. du Moulin GC: Lessons learned in the scale-up of quality systems for a cell therapy: An 8,000 patient experience with autologous chondrocyte implantation. *Proceedings of the Standardization of Quality Control of Cell and Gene Therapy*

Products. European Directorate for the Quality of Medicines, Strasbourg, France, 2003.

73. Kielpinski G, Prinzi S, Duguid J, Price A, and G du Moulin. Automated sterility testing: An alternative approach to compendial sterility testing of cell therapy products. *Proceedings of the International Society for Cell Therapy Annual Meeting*. Phoenix, AZ 2003.

74. Kielpinski G, Bonn T, Maria M, LaForest R, Schutz B, Lessor J, Duguid J, and G du Moulin. Use of a polymerase Chain Reaction (PCR) mycoplasma assay as a drug product component release test for a cell therapy cancer vaccine product. *Proceedings of the 10th International Society for Cell Therapy Annual Meeting*, Dublin, Ireland 2004.

75. Prinzi S, Duguid J, Kielpinski G, Araneda M, Galvez G, Ostrovskaya T, du Moulin G. Automated Rapid Microbial Detection for an autologous cell therapy: A twelve month review of sterility testing data. *Proceedings of the 2006 AAPS Annual Meeting and Exposition*, San Antonio Texas, 2006.

75. du Moulin GC, Prinzi S, Kielpinski G, Araneda M, Galvez, Ostrovskaya T, Duguid J. Automated rapid microbiological detection for the pharmaceutical industry. Experience with validation and implementation for an autologous cell therapy product. *New Microbiology Chapter of the European Pharmacopeia*. European Directorate for the Quality of Medicines, Strasbourg, France, 2006.

76. Duguid J, Prinzi S, Kielpinski G, Galvez G, Ostrovskaya T, du Moulin G. Automated rapid microbial detection for an autologous cell therapy: A twelve month review of sterility testing data. *Proceedings of the 13th Annual International Society for Cell Therapy*, Sydney Australia, 2007.

77. Duguid J, Kielpinski G, du Moulin G, Seymour B. Application of a risk based approach to optimize a rapid mycoplasma test for cell therapy and tissue-engineered products. *Proceedings of the American Association of Pharmaceutical Scientists*, 2008.

78. Kielpinski GL, Parker A, Dethlefsen S, O'Brien C, Wicks J, Dono D, du Moulin G, Skrabut EM. Compatibility of anti-infective agents with cultured epidermal autografts: An in vitro assessment of cytotoxicity. *Proceedings of the 42nd Annual Meeting of the American Burn Assn*, 2010.

78. Balkovic E and du Moulin GC. Biocide effectiveness for the elimination of *Acinetobacter baumannii* from work surfaces in biopharmaceutical manufacturing. *Proceedings of the 114th General Meeting of the American Society for Microbiology* (2014).